Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2026)

Amphastar Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 143.53% year-over-year to $14.4 million in Q1 2026; TTM through Mar 2026 was $14.4 million, a 143.53% increase from a year earlier, with the FY2025 full-year figure at $14.5 million, up 31.87% from the prior year.
• Long-Term Investments fell to $14.4 million in Q1 2026 per AMPH's latest filing, from $14.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $14.7 million in Q4 2023 and bottomed at $972000.0 in Q3 2023.
• The 5-year median for Long-Term Investments is $5.9 million (2025), against an average of $7.5 million.
• Across the five-year window, Long-Term Investments soared 867.08% in 2024 and plunged 79.41% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $4.5 million in 2022, then jumped by 226.33% to $14.7 million in 2023, then retreated by 25.12% to $11.0 million in 2024, then surged by 31.87% to $14.5 million in 2025, then declined by 0.69% to $14.4 million in 2026.
• Per Business Quant, the three latest AMPH Long-Term Investments figures stand at $14.4 million (Q1 2026), $14.5 million (Q4 2025), and $13.3 million (Q3 2025).